Eukaryotic DNA topoisomerase II is an abundant nuclear enzyme involved in regulating the conversion of DNA between different topological isoforms (42, 60) . It fulfills essential functions in DNA replication (41, 53) and chromosome segregation during both mitosis (26, 27) and meiosis (46) , and it is thought to play a key role in certain types of DNA recombination events (8, 10, 22, 30, 48) . The enzyme has furthermore been suggested to constitute a component of nuclear scaffold structures (3, 23) , where it may be involved in chromosome condensation (4, 58) and decondensation (45) .
Topoisomerase II binds to DNA as a dimer and cleaves its DNA substrate with a 4-bp stagger (40, 60) at sites with loosely defined sequences (54) . Upon DNA cleavage, each subunit of topoisomerase II becomes transiently ligated to the 5Ј ends of the respective DNA strands through an O 4 -phosphotyrosine bond involving a tyrosine residue in the active site of the protein (7, 36) . Catalytic activity is ATP dependent, and it is performed by passing one intact DNA helix through the enzyme-mediated double-stranded DNA break, followed by rejoining of the DNA strands (42) .
Although the mechanics of topoisomerase II function have been characterized in great detail, little information has emerged about the functional organization of the enzyme. Proteolysis studies on purified topoisomerase II from Saccharomyces cerevisiae (35) , Schizosaccharomyces pombe (50) , Drosophila melanogaster (34) , and humans (9) suggest that the enzyme is composed of three major structural domains, of which two are constituted by the conserved N-terminal and central parts of the protein and a third is constituted by the highly divergent C-terminal region.
The fragment originating from the N-terminal third of topoisomerase II has been predicted to contain the ATPase activity on the basis of its colinear homology to ATP-binding subunit B of the bacterial equivalent of topoisomerase II, DNA gyrase (44) . The central part of the eukaryotic enzyme shows homology to subunit A of DNA gyrase, which functions as the catalytic subunit in the bacterial enzyme (44) . Therefore, this highly conserved core of topoisomerase II is believed to constitute a catalytic subdomain capable of binding to and cleaving-religating DNA. In accordance with this, a crystal structure of a 92-kDa fragment of S. cerevisiae topoisomerase II has recently identified a specific DNA binding motif in this central core region (11) , and biochemical experiments have previously identified Tyr-783 as the active-site tyrosine involved in DNA cleavage and religation (67) . The hydrophilic C-terminal part of the protein is highly divergent with respect to both sequence and extent and has no equivalent in bacterial gyrase (50, 69) . Analyses of mutant topoisomerase II from S. pombe (50) , S. cerevisiae (17) , and D. melanogaster (20) have shown that a large proportion of the C-terminal region is dispensable for cell viability and has no detectable effect on enzymatic activity in vitro.
Here we report a comparative analysis of the functional importance of the conserved and unconserved regions in human topoisomerase II␣ and S. cerevisiae topoisomerase II. A yeast plasmid-shuffling system was established to investigate the ability of mutant topoisomerase II proteins to complement yeast top2 deletion strains and to enable purification of mutant proteins for in vitro analysis. By sequence alignments, 13 highly conserved domains separated by unconserved or differently spaced sequences were defined in the topoisomerase II proteins. The importance of spacing between the conserved domains was assessed by insertion of linkers of various lengths into the spacer sequences, and the importance of the conserved domains was tested by individual deletion of these. The specific functions of the C-terminal end of human topoisomerase II␣ and S. cerevisiae topoisomerase II were studied by C-terminal truncations. The mutant proteins were characterized with respect to complementation ability, cellular localization, and in vitro catalytic activity.
MATERIALS AND METHODS

Abbreviations.
The following abbreviations are used in this report: DAPI, 4Ј,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; 5-FOA, 5Ј-fluoroorotic acid; kDNA, kinetoplast DNA; NLS, nuclear localization sequence; PAGE, polyacrylamide gel electrophoresis; SDS, sodium dodecyl sulfate; TPI, triose phosphate isomerase.
Yeast strains, media, and plasmids. Yeast strains Y700 (MAT␣ ura3 leu2 his3 trp1 ade2) and BJ5462 (MAT␣ ura3 leu2 pep4::HIS3 prb1 trp1 can1) were used to generate top2 deletion strains BJ200 and BJ201, respectively. The endogenous TOP2 gene was disrupted by integration of yeast selection marker TRP1 into an internal deletion of the S. cerevisiae TOP2 gene. Yeast cells were transformed by using a modification of the lithium acetate method of Ito et al. (28) . The media and other yeast procedures used were essentially those described by Sherman (49) . Plasmid pBY105 contains the yeast TPI promoter inserted into the polylinker region of LEU2/ARS-CEN plasmid pRS315 (52) . This low-copy plasmid was used as the plasmid backbone for introduction of all mutant top2 cDNAs into S. cerevisiae. Plasmid pYTO300 contains the wild-type S. cerevisiae TOP2 cDNA under control of the TPI promoter. The plasmid was constructed by inserting a BglII-NotI topoisomerase II fragment from YEpTOP2-PGAL1 (kindly provided by J. C. Wang) into pBY105 digested with BamHI and NotI. Plasmid pYYP7 is a modified version of pYTO300 in which PCR was used to insert a tag encoding the c-Myc epitope, a hexahistidine tail, a stop codon, and a NotI restriction site just upstream of the endogenous stop codon. Plasmid pHT300 is identical to pYTO300 but carries the wild-type human ␣ TOP2 cDNA instead of the yeast TOP2 cDNA. The human ␣ TOP2 cDNA was cloned in two steps from pBS-hTOP2 (kindly provided by J. C. Wang) into a modified version of pBSII (KSϪ). From this plasmid, the NheI-NotI fragment, containing the human ␣ TOP2 cDNA, was cloned into pBY105, which had been cut with SpeI and NotI. Plasmid pHT212 is the human counterpart of pYYP7, containing the c-Mychexahistidine tag inserted at the C-terminal end of pHT300. Plasmid pSp100 contains the wild-type S. pombe TOP2 gene under the control of its own promoter. It was constructed by inserting the HindIII fragment encoding the S. pombe TOP2 gene (kindly provided by M. Yanagida) into URA3/ARS-CEN plasmid pRS316 (52) .
Construction of mutant topoisomerase II proteins. Single restriction site insertion mutant forms of the human ␣ and S. cerevisiae TOP2 cDNAs were constructed by site-directed mutagenesis as described by Kunkel (32) . The oligonucleotides used for mutagenesis contain the recognition sequence of restriction enzyme SalI or XhoI, thereby resulting in mutant topoisomerase II proteins having two additional amino acids, V and D or L and E, respectively, inserted. For insertion positions, see Fig. 2 and 3 . Constructs containing restriction site insertions at two positions in the TOP2 cDNA were made by site-directed mutagenesis with a single-stranded template from single restriction site insertion mutants. All double restriction site insertion mutants were designed with one XhoI site and one SalI site flanking the domain of interest. Deletion mutants were subsequently created by digesting the double restriction site insertion mutants with SalI and XhoI, followed by ligation of the compatible ends. Twelveamino-acid insertion mutants of human topoisomerase II␣ were generated from the single restriction site insertion mutants by insertion of the 30-bp linker 5Ј-TCGACCTGCCTAGGCTCGAGGGGCCCAGAC-3Ј, which is flanked by SalI and XhoI sites and contains a central XhoI site. PCR was used to verify the orientation of the inserted linkers. Mutants containing 7-amino-acid insertions were generated from the 12-amino-acid insertion mutants by XhoI or XhoI-SalI digestion. A panel of carboxy-terminal truncations were generated by introducing a linker encoding the human c-Myc epitope followed by six histidine residues into the SalI or XhoI site of the single restriction site insertion mutants. The sequences of the c-Myc-His linker oligonucleotides are 5Ј-TCGAGGCACAT ATGCCTAGGGAACAAAAGTTGATCTCTGAAGAAGACTTGAACGTG CACCATCACCACCATCATGTGCACTAGCЈ-3 (top strand), and 5Ј-GGC CGCTAGTGCACATGATGGTGGTGATGGTGCACGTTCAAGTCTTCTT CAGAGATCAACTTTTGTTCCCTAGGCATATGTGCCЈ-3 (bottom strand). Truncation mutants h⌬C1233, h⌬C1263, h⌬C1296, and h⌬C1352 were generated from pHT300 by introducing an XhoI restriction site and a termination codon followed by a NotI site at the indicated amino acid positions by PCR. Pfu polymerase from Stratagene was used for the PCR. The XbaI-NotI fragment from each reaction was used to replace the corresponding XbaI-NotI fragment of pHT300, within which the 3Ј end of the human ␣ TOP2 cDNA lies. The c-MycHis linker was subsequently inserted into the XhoI site. Plasmid pYYP8 contains the S. cerevisiae TOP2 cDNA, in which the active-site tyrosine Tyr-783 has been mutated to a serine residue by site-directed mutagenesis with pYYP7 as the template DNA. In plasmid pHT213, the tyrosine at position 804 has been changed to a serine by site-directed mutagenesis with pHT212 as the template DNA. Linker insertion mutants, deletion mutants, and C-terminal truncation mutants of yeast topoisomerase II and human topoisomerase II␣ were tested for expression in yeast strains Y700 and BJ201. Expression of linker insertion mutants and yeast deletion mutants was examined in crude yeast extract. Following extraction of cells derived from 50-ml cultures, the protein content was measured with the Bradford assay (12), and equal amounts of protein were loaded onto SDS-protein gels. The C-terminal truncation mutants and human deletion mutants were affinity purified, and eluted fractions were corrected for protein concentration by the Bradford assay prior to gel electrophoresis. SDS-PAGE was performed as described by Laemmli (33) . Topoisomerase II mutants containing the c-Myc epitope were visualized by immunostaining with mouse monoclonal antibody MYC1-9E10.2. Yeast topoisomerase II mutants without the c-Myc epitope were detected by immunostaining with an anti-topoisomerase II antibody raised against Drosophila topoisomerase II. Human topoisomerase II mutants without the c-Myc epitope were visualized by the commercially available Cambridge anti-topoisomerase II antibody. As indicated by immunostaining, different topoisomerase II mutant proteins are expressed to similar levels within the range of a factor of 2. Mutants unable to complement a top2 null mutation were further tested by nucleotide sequencing. In cases in which the mutants contained a hexahistidine tail, the enzymes were purified and their ability to decatenate kDNA was tested in vitro.
Oligonucleotides. All synthetic oligonucleotides were synthesized on a 381A DNA synthesizer from Applied Biosystems. The oligonucleotides used for mutagenesis were all 34-to 48-mers (data not shown).
Gene disruption. Haploid yeast strains BJ200 and BJ201, carrying a top2 disruption, were constructed from Y700 and BJ5462, respectively, by the onestep gene disruption method (47) . A linear DNA fragment containing the TRP1 gene flanked by the N-terminal 163 amino acids and the 391 C-terminal amino acids of S. cerevisiae topoisomerase II was used for transformation of Y700 and BJ5462. The cells were cotransformed with plasmid pSp100 carrying the S. pombe TOP2 gene, which acts as a substitute for topoisomerase II activity. Genomic DNA was isolated from stable LEU2 transformants and examined by Southern blotting to verify integration of TRP1 into the endogenous TOP2 gene.
Complementation assay. Mutant top2 constructs were transformed into haploid top2 null strain BJ200 or BJ201, and colonies from selection plates were streaked onto media containing 5-FOA (1 mg/ml) to counterselect against the URA3 plasmid carrying the S. pombe TOP2 gene. Colonies were submitted to PCR screening with primers specific to the S. pombe TOP2 gene to ensure that the URA3 plasmid was effectively lost from the cells. Generation times of transformed yeast cells were measured on cultures grown to late log phase overnight and subsequently diluted to an optical density at 600 nm of 0.1 in selective medium (without Leu) to allow continued growth. Aliquots were removed at various times; and the optical density at 600 nm was measured.
Purification of topoisomerase II mutants. Human topoisomerase II␣ and S. cerevisiae topoisomerase II constructs containing the hexahistidine sequence were transformed into protease-deficient strain BJ201. Cells were grown overnight in 50 ml of selective medium (without Leu) containing 2% glucose, transferred to 500 ml of selective medium for further growth, and harvested at an optical density at 600 nm of 0.8 by centrifugation. Crude yeast extract was prepared with 2 volumes of extraction buffer (50 mM Tris [pH 7.8], 1 M NaCl, 1 mM phenylmethylsulfonyl fluoride) and 1 volume of acid-washed glass beads (425 to 600 m; Sigma) by vortexing at 4ЊC for 30 min. Glass beads and cell debris were removed by centrifugation at 4,000 ϫ g for 10 min, and the supernatant was further centrifuged for 20 min at 15,000 ϫ g. After filtration (0.65-m-pore-size filters), the crude extract was loaded onto an Ni 2ϩ -nitrilotriacetic acid-agarose column (matrix purchased from Qiagen). The column was washed with 5 volumes of buffer A (15 mM imidazole [pH 8], 1 M NaCl, 10 mM KPO 4 [pH 8], 10% glycerol) before protein was eluted with buffer B (500 mM imidazole, 1 M NaCl, 10 mM KPO 4 [pH 8], 10% glycerol) in a gradient of imidazole ranging from 15 to 500 mM. Fractions were collected, and the samples were submitted to SDS-PAGE on 8.5% polyacrylamide gels.
In vitro DNA decatenation. Activity of purified mutant topoisomerase II proteins was determined in a DNA decatenation assay with kDNA. Purified topoisomerase II enzyme was incubated with 300 ng of kDNA in 1 mM ATP-5 mM MgCl 2 -1 mM dithiothreitol-0.5 mM EDTA-50 mM bis-Tris-propane (pH 8.0)-0.12 M potassium glutamate in a total volume of 20 l. The samples were incubated for 30 min at 37ЊC and subsequently submitted to electrophoresis on a 0.7% agarose gel.
Indirect immunofluorescence. Wild-type and mutant c-Myc-His-tagged topoisomerase II proteins were expressed in BJ201 and prepared for immunostaining essentially as previously described (6) . Mouse monoclonal antibody MYC1-9E10.2 was used to detect the expressed proteins carrying the c-Myc-His tag. The secondary antibody was fluorescein-conjugated F(abЈ) 2 fragments of swine antimouse immunoglobulin G (DAKO A/S). Yeast nuclei were counterstained with DAPI (Sigma). The preparations were examined with a Leitz DM epifluorescence microscope coupled to a cooled charge-coupled device camera (PM512; Photometrics) at a magnification of ϫ1,200. Camera control and image acquisition were done with an Apple Quadra 800 equipped with imaging software from IPLab (IPLabSpectrum). Fluorophores were selectively imaged with filters specially prepared as described by Pinkel et al. (43) . Signals from DAPI and FITC were visually distinct and readily identifiable by inspection with appropriate filters.
RESULTS
Human topoisomerase II␣ complements mitotic growth in an S. cerevisiae topoisomerase II deletion strain. S. cerevisiae provides the most efficient eukaryotic system to test large numbers of mutations in an essential gene for effects on functional complementation. We have used a modified version of the plasmid-shuffling technique of Mann et al. (39) to study the ability of wild-type and mutant forms of human topoisomerase II␣ and S. cerevisiae topoisomerase II to complement a yeast top2 deletion background. The chromosomal TOP2 gene was disrupted by insertion of the structural TRP1 gene (see Materials and Methods), while the essential topoisomerase II activity was provided by the S. pombe TOP2 gene on a low-copy URA3-based plasmid. Wild-type human topoisomerase II␣ and S. cerevisiae topoisomerase II expressed from LEU2-based vectors both complement the genomic disruption following loss of the S. pombe TOP2 gene by growth on 5-FOA (Fig. 1) . The S. cerevisiae enzyme allows slightly better growth of the yeast cells than does human topoisomerase II␣ ( Table 1 ). The findings on complementation are in agreement with earlier studies, in which wild-type S. cerevisiae and a recombinant form of human topoisomerase II␣ having the N-terminal part substituted by the equivalent sequence of the yeast enzyme were able to sustain mitotic growth in a top2 temperature-sensitive strain. Our observation adds to the general conclusion that topoisomerase II enzymes from a wide variety of eukaryotic origins are functionally interchangeable (2, 17, 57, 61, 68) .
In the S. cerevisiae enzyme, the active-site tyrosine has been mapped to Tyr-783 (67) , and in our study, substitution of tyrosine 783 with serine abolished the ability of the yeast cDNA to complement the TOP2 disruption (Fig. 1) . From homology, Tyr-804 has been predicted to be the active-site tyrosine of human topoisomerase II␣. Consistent with this prediction, complementation was abolished when tyrosine 804 was substituted with serine in human topoisomerase II␣, and the resulting enzyme was unable to perform DNA decatenation in vitro (Table 1 ). This result supports the hypothesis that residue 804 in human topoisomerase II␣ is the active-site residue and indicates that the ability to complement is linked to enzymatic activity.
Insertion of linkers into unconserved spacer regions of human topoisomerase II␣ and S. cerevisiae topoisomerase II.
Sequence alignments of topoisomerase II enzymes of different eukaryotic origins reveal a complex pattern of conserved regions that cover approximately 70% of the amino acid sequence (57, 69) . Conservation is most pronounced in the Nterminal part of topoisomerase II, where highly conserved regions are interspersed with comparatively short "spacer" regions, which vary significantly in sequence between species and, in some cases, by one or a few amino acids in length. Towards the C-terminal end of topoisomerase II, conservation decreases and the most C-terminal 30% of the protein appears to have diverged entirely. Alignment of the amino acid sequences of human topoisomerase II␣ (56) and S. cerevisiae topoisomerase II (24) has revealed an overall sequence identity of 40%. From alignments of the two sequences with the Pileup program of the Genetics Computer Group package with gap creation and gap extension penalty settings of 3.00 and 0.10, respectively, we have defined 13 conserved regions in topoisomerase II that are separated by unconserved spacer sequences ( Fig. 2 and 3 ). The conserved regions exhibit an average identity of approximately 60%, with the exception of the most C-terminally located of the 13 domains (33% identity), whereas the spacer sequences are defined as regions of low homology, with an average identity of approximately 10%.
As an initial approach to examine the functional organization of topoisomerase II, we probed whether the spacer regions can be assumed to have a more flexible structure of less importance for topoisomerase II function. To investigate this, linkers were introduced into the spacer regions of human topoisomerase II␣ and S. cerevisiae topoisomerase II and the complementation abilities of the mutant proteins were tested in the yeast deletion strains (Fig. 2 and 3) .
In each spacer region of human topoisomerase II␣, a twoamino-acid linker with a DNA sequence corresponding to the recognition sites for restriction endonuclease XhoI or SalI was inserted (Fig. 2) . In three cases, at amino acid positions 112, FIG. 1. Human topoisomerase II␣ complements functions essential for mitotic growth in S. cerevisiae deletion strains. Deletion strain BJ200 was transformed with LEU2 plasmids carrying TPI-expressed topoisomerase II cDNAs, and cells were grown on selective plates (without Leu) containing 1 mg of 5-FOA per ml (ϩFOA) or no 5-FOA (ϪFOA). The expressed topoisomerase II proteins are designated as follows: y-wt, wild-type S. cerevisiae topoisomerase II; y-Y 783 3S, S. cerevisiae topoisomerase II with a tyrosine-to-serine mutation at position 783; h ␣-wt, wild-type human topoisomerase II␣; h ␣-Y 804 3S, human topoisomerase II␣ with a tyrosine-to-serine mutation at position 804; con, control in which BJ200 was transformed with pBY105 containing the TPI promoter only. Similar results were obtained with complementation in strain BJ201. 350, and 407, insertion causes complete loss of viability for the host strain. The inability to complement is not due to lack of expression or stability of the mutant proteins, since the linker insertion mutants were expressed at a level similar to that obtained with wild-type human topoisomerase II␣ ( Fig. 2 ; see Materials and Methods). To rule out the possibility that the minor effect observed after the introduction of two-amino-acid insertions was due to the small size of the linkers, we next investigated the importance of the extent of the inserted linker. Thus, oligonucleotides varying in length were inserted into the already introduced XhoI and SalI restriction sites, resulting in total insertions of 7 and 12 amino acids including one and two proline residues, respectively. Insertion of the longer peptides into the spacer regions of human topoisomerase II␣ at the positions indicated in Fig. 2 does not change the viability pattern except at one position, residue 828, where both 7-and 12-amino-acid insertions inhibited complementation, in contrast to the 2-amino-acid insertion. This position is in the vicinity of the active-site tyrosine of the enzyme, and a longer insertion here might obstruct the configuration of the active site. The linker insertion analysis thus indicates that most of the domains defined by the sequence alignment can fold as Fig. 2) . On the basis of the very similar patterns obtained with linkers of different lengths in human topoisomerase II␣, only linkers encoding two amino acids were inserted into the spacer regions of S. cerevisiae topoisomerase II. As seen in Fig. 3 , insertion into the spacers was tolerated in the yeast enzyme, except between domains 5 and 6. Insertion into this spacer is also detrimental in human topoisomerase II␣, and thus, there seems to be a structural dependency between domains 5 and 6 in both enzymes. It is unclear why insertion between domains 1 and 2 does not affect the complementation ability of the yeast enzyme, but the result obtained indicates that the most Nterminal region of human topoisomerase II␣ is more restricted than the corresponding region of the yeast enzyme.
Individual deletion of conserved domains.
To investigate whether each conserved domain, as defined by the sequence alignment, is necessary for the essential functions of topoisomerase II, the effects of single domain deletions were studied. The 11 most N-terminally located domains in human topoisomerase II␣ (Fig. 4A) and S. cerevisiae topoisomerase II (Fig. 4B) were deleted individually, whereas the two most C-terminal domains were deleted by C-terminal truncations (see Fig. 5 and 7 for the human and yeast enzymes, respectively). All constructs expressing human topoisomerase II␣ (Fig.  4A) or S. cerevisiae topoisomerase II (Fig. 4B) with a deletion of one of the conserved domains were unable to complement the yeast deletion strains.
It is noteworthy that none of the human topoisomerase II␣ or S. cerevisiae topoisomerase II deletion mutants behaved as dominant lethals, since a TOP2 wild-type strain (BJ5462) expressing the individual deletion mutant enzymes showed no sign of reduced growth (data not shown). This observation indicates that the expressed mutated enzymes do not interfere with the endogenous enzyme to a level detectable in our system. Neither do they interact with DNA in a way that influences the phenotype of the cells.
To rule out the possibility that the complementation inability of the deletion mutants reflects a lack of protein expression or stability, expression was tested by immunoblotting ( Fig. 4 and Materials and Methods). In all of the transformants tested, only a single band of the expected size was observed with the respective antibodies. The intensities of the antibody-specific bands furthermore indicate that the deletion mutants are expressed at similar levels. The human mutants were constructed with a C-terminal bicomposite protein tag consisting of an 11-amino-acid c-Myc epitope and a hexahistidine tail, enabling detection of the proteins by monoclonal antibody MYC1-9E10.2 and purification of mutant proteins by metal-chelating affinity chromatography, respectively. After purification of the individual human topoisomerase II␣ enzymes containing a deletion of one of the conserved domains, the enzymes were analyzed for the ability to decatenate kDNA. In accordance with their inability to complement the yeast deletion strains, all of the human deletion mutant enzymes lacked the ability to decatenate kDNA (Fig. 4A) . Thus, each conserved domain in topoisomerase II seems either to be essential for folding of a functional protein or to contain sequences that participate in functions essential for enzymatic activity.
C-terminal truncations of human topoisomerase II␣ and S. cerevisiae topoisomerase II. To assess the importance of the largest unconserved domain in topoisomerase II, the C-terminal region, a series of vectors expressing proteins with Cterminal truncations were constructed. The majority of constructs carried the C-terminal bicomposite protein tag to allow further analysis of the enzymes in vitro.
In human topoisomerase II␣, the variable C-terminal region covers the approximately 300 amino acids extending from amino acid ϳ1200 (63) . When the 31 most C-terminal amino acids were removed by truncation to residue 1499 (h⌬C1499), we saw no detectable effect on the ability of the mutant enzyme to complement in S. cerevisiae, and truncation to residue 1352 (h⌬C1352) only slightly impaired the growth rate of the host strain (Fig. 5) . Any further truncations, the least extensive tested being to residue 1296 (h⌬C1296), abolished complementation. To rule out the possibility that the observations made on complementation ability were due to low expression or instability of certain truncated proteins, Western blotting (immunoblotting) was performed with monoclonal antibody MYC1-9E10.2 (Fig. 5) . From the immunostaining obtained, it appears that the truncated proteins are expressed at similar FIG. 3 . Linker insertion analysis of regions separating conserved domains in S. cerevisiae topoisomerase II. The conserved domains are shown as shaded boxes. They are separated by sequences of less homology or different spacing into which a two-amino-acid linker, VD or LE, was introduced at the indicated positions. The ability of the linker insertion mutant enzymes to complement BJ201 is indicated by plus and minus signs. wt-yTOPII illustrates wild-type S. cerevisiae topoisomerase II; the numbers refer to amino acid residues. The designation of each mutant construct refers to the insertion position and the extent of the inserted linker. The mutant protein negative for complementation was expressed at a level similar to that of wild-type yeast topoisomerase II, as observed by immunostaining (data not shown), and the construct was sequenced throughout the TOP2 cDNA to verify its integrity. To test whether the ability to complement correlates with enzymatic activity, a number of the truncated proteins were affinity purified on nickel columns. Human topoisomerase II␣ remained capable of decatenating kDNA when the truncations only removed unconserved C-terminal sequences (h⌬C1352, h⌬C1296, h⌬C1263, and h⌬C1233), whereas enzymatic activity was lost when the most C-terminal of the conserved domains was deleted (h⌬C1121) (Fig. 5) .
In the proteins expressed from three constructs, h⌬C1296, h⌬C1263, and h⌬C1233, the ability to decatenate kDNA was retained and yet the ability to complement the endogenous topoisomerase II disruption was lost (Fig. 5) . The results demonstrate that an enzymatically active truncated human protein, at the expression levels obtained in these experiments, is insufficient to provide the topoisomerase II functions required for mitotic growth.
To seek an explanation for the role of the sequences in the nonconserved C-terminal region that are required for complementation but not for kDNA decatenation, we next studied the cellular distribution of the truncated human proteins in yeast cells (Fig. 6 ). Immunofluorescence studies showed that overexpressed full-length human topoisomerase II␣ is located mainly in the nucleus (Fig. 6A) . Thus, specific nuclear localization of human topoisomerase II␣ appears to be functional in yeast cells. Truncation of the human protein to residue 1352 ( Fig. 6B ) decreased nuclear staining and increased cytoplasmic staining. An even higher level of cytoplasmic staining was obtained with a mutant protein truncated to residue 1296 (data not shown), whereas only cytoplasmic staining was evident with a protein truncated to residue 1233 (Fig. 6C) .
In conclusion, it appears that in human topoisomerase II␣, sequences between residues 1352 and 1233 are essential for specific nuclear localization. According to our observations, even partial impairment of the localization mechanism, by C-terminal truncations beyond residues 1352 to 1296, correlates with loss of complementation. Thus, failure to complement may be correlated with the lower content of the truncated human enzyme in the yeast nucleus.
In S. cerevisiae topoisomerase II (Fig. 7) , truncations until the most C-terminal of the conserved domains (y⌬C1236 and y⌬C1208) had no detectable effect on the ability to complement, and the purified recombinant enzymes were capable of decatenation in vitro. Further truncations removing one, two, or three of the most C-terminal conserved domains (y⌬C1103, y⌬C941, and y⌬C895) caused complete loss of complementation ability. The enzyme truncated at residue 1103 was affinity purified, but no decatenation activity was detectable. As the truncated proteins are expressed at similar levels, the inability to complement correlates with loss of decatenation activity in the yeast enzyme. It has previously been pointed out that the unconserved C-terminal region of S. cerevisiae topoisomerase II contains a sequence motif that may act as a nuclear localization signal in the region between residues 1171 and 1334 (17, 21) . In our study, proteins truncated to residue 1236 gave a specific immunofluorescence staining of the nucleus, whereas further deletion of 28 amino acids to residue 1208 abolished specific nuclear staining, and this truncated enzyme was found mainly in the cytoplasm. Thus, a major nuclear localization signal seems to be located between residues 1236 and 1208. Because the construct with a deletion from residue 1208 still complemented (Fig. 7) , it appears that with the expression level obtained with the TPI promoter, specific localization of the yeast enzyme to the nucleus is not a prerequisite for performance of the functions essential for mitotic growth.
DISCUSSION
Domain organization in eukaryotic topoisomerase II as deduced by linker insertion mutagenesis. Conservation between human topoisomerase II␣ and S. cerevisiae topoisomerase II is distributed in 13 different regions as defined in our study, where the first 8 cover the N-terminal 650 amino acids in topoisomerase II, showing colinear homology to bacterial gyrase subunit B (44, 50, 63) , and the last 5 domains cover the central part of the eukaryotic enzyme, stretching from approximately amino acid 650 to amino acid 1200. This part shows homology to subunit A of the bacterial enzyme (38) and is flanked in the surrounding spacers by proteolytic cleavage sites (34, 35, 50) . In the present study, insertion of a two-amino-acid linker into 10 of the 13 spacer regions in human topoisomerase II␣ (Fig. 2) and 12 of the 13 spacer regions in S. cerevisiae topoisomerase II (Fig. 3) had no detectable effect on the complementation of a top2 null strain. Linkers abolishing complementation were all located in the approximately 400 N-terminal amino acid residues. Insertion of more extensive linkers containing proline residues into the human topoisomerase II␣ protein produced results similar to those obtained with the two-amino-acid insertions. The only exception was insertion of the linkers at position 828 in the vicinity of the active site, which gave rise to a noncomplementing enzyme. The results obtained thus indicate that the majority of the defined spacer regions are of minor importance for topoisomerase II function and are more likely to represent flexible joints between conserved domains. It is noteworthy that in a recent investigation by Lee and Hsieh (34) in which random linker insertion was used to study the organization of Drosophila topoisomerase II, the majority of insertion points corresponding to the conserved domains defined in this study were found to abolish complementation of a top2 temperature-sensitive yeast strain. In agreement with our observations, this work also indicated that the structure of the N-terminal part of the protein is highly constrained.
The five most N-terminal linker insertion positions in our study are located in a region corresponding to the crystallized 43-kDa N-terminal fragment of gyrase subunit B that forms a dimer in the presence of an ATP analog (66) . The crystal structure reveals two internal subdomains separated by a hinge at amino acid position 220. One of our insertion positions (residues 269 in the S. cerevisiae enzyme and 282 in the human enzyme) is located in this hinge region, and the complementation ability of mutants containing up to 12 amino acids at this position indicates that a similar structural domain organization exists in eukaryotic topoisomerase II enzymes. Intriguingly, complementation was also achieved with mutant enzymes containing a linker at positions 7 and 29 in the yeast and human enzymes, respectively, corresponding to Tyr-5 in gyrase subunit B, which, from the crystal structure, has been shown to be directly involved in ATP binding and dimerization of the Nterminal claws (66) . The complementation abilities of these insertion mutants indicate that this region, no matter its important function, can sustain the perturbations derived from linker insertion. Two human mutant enzymes carrying insertions at positions 112 and 350 were unable to complement. These positions fall into the region constituting the interior walls of the cavity enclosing DNA in gyrase subunit B, and insertions here would therefore be expected to be detrimental for enzyme function. It is, however, puzzling that linker inser-tion at the equivalent position in yeast topoisomerase II gave a functional enzyme.
In both human topoisomerase II␣ and S. cerevisiae topoisomerase II, linker insertion between conserved domains 5 and 6 at positions 407 and 398, respectively, yielded enzymes unable to sustain mitotic growth. This spacer sequence is located in a region between the ATP binding domain and the remaining part of the gyrase subunit B-homologous region in eukaryotic topoisomerase II (the BЈ fragment [11] ). It is supposed to be involved in the conformational changes that take place during ATP binding because it is sensitive to proteolytic degradation only in the absence of ATP. Although the spacer is protease sensitive, our observation indicates that positioning of these respective domains is highly important for ATP-derived transitions in the enzyme.
The seven most C-terminally located linker insertion positions fall into the region from residues 400 to 1200 in S. cerevisiae topoisomerase II, and recently the crystal structure of this 92-kDa fragment has been revealed (11) . None of the linkers are inserted in secondary structural entities such as ␣ helices and ␤ pleated sheets but rather lie in relative hydrophilic segments separating such structures.
The crystal structure presented by Berger et al. (11) reveals two dimerization regions, where the primary dimer interface is present in the C-terminal part of the fragment involving amino acids 1031 to 1046 and 1114 to 1130 and the other involves residues in the BЈ region stretching from amino acids 420 to 680. One of our linker insertion sites maps to position 1103 in S. cerevisiae topoisomerase II, between the two identified Cterminal dimerization regions. Since this region tolerates linker insertion in both yeast topoisomerase II and human topoisomerase II␣, our results indicate that exact spacing is not a prerequisite for functional dimerization, and this area might constitute a more flexible structure. The fact that a fragment spanning residues 1109 to 1163 in S. cerevisiae topoisomerase II recently has been found to interact specifically with Sgs1, a eukaryotic homolog of the bacterial helicase RecQ (64), suggests that this C-terminal region plays a major role in proteinprotein interactions, further supporting a more accessible and flexible structure of this region. To this end, it is likely that the lack of catalytic activity of C-terminal truncation mutants yC⌬1103 and hC⌬1121 in our study is due to absence of subunit dimerization.
On the basis of the crystal structure, it has been suggested that ATP-dependent dimerization of the BЈ fragments involves residues Ile-540, Leu-551, and Leu-557 on one subunit and Tyr-602 on the other (11) . In this respect, it is interesting that two of our linker insertions, at positions 514 and 570 in S. cerevisiae, located in the same structural domains as the interacting residues, were tolerated without functional consequences. Our observation implies either that this region is not sensitive to perturbations or that the interaction seen in the crystal structure is merely a result of crystal packing and is absent in the intact enzyme. The latter explanation is supported by a previously reported linker insertion mutant of Drosophila topoisomerase II that retained its catalytic ability FIG. 5 . Effects of C-terminal truncations of human topoisomerase II␣ on complementation (Compl.) and enzymatic activity. C-terminally truncated topoisomerase II constructs were fused to a bicomposite tag (-c-myc tag -His 6 ). The abilities of the fusion constructs to complement were tested in strain BJ201. Brackets indicate that identical complementation results were obtained with constructs both with and without the bicomposite tag. Lack of brackets indicates that only the depicted construct was tested. Expression of C-terminally truncated constructs with the synthetic linkers was tested by immunostaining with MYC1-9E10.2. Affinity-purified proteins were tested for decatenation abilities as indicated. C-terminal endpoints of the topoisomerase II sequences are indicated above each construct. wt-hTOPII with and without the tag refer to plasmids pHT212 and pHT300, respectively. ‫,ء‬ cells showing a slightly reduced growth rate compared with cells expressing wild-type topoisomerase II (nd, not determined).
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on February 20, 2013 by PENN STATE UNIV http://mcb.asm.org/ following insertion of a hydrophilic linker at a position equivalent to amino acid 597 of S. cerevisiae topoisomerase II (34) . The only spacer in the region from amino acids 400 to 1200, where a structural dependency seems to exist between the flanking conserved domains, is the spacer between domains 9 and 10. Insertion of more extensive linkers at position 828 in human topoisomerase II␣ was detrimental to enzyme function. Since this position is in the vicinity of a general DNA binding motif detected from the crystal structure, it is plausible that insertion of 7 or 12 residues at this point might influence the stability of the enzyme-DNA complex by interfering with this motif.
The two most C-terminally located insertion positions are present in a region of the enzyme which, deduced from the crystal structure, forms the upper part of the DNA binding cavity and might be involved in further stabilization of the protein-DNA complex. These sites tolerate perturbations derived from insertions of up to 12 amino acids, suggesting that this region folds into a more flexible structure. On the basis of the architecture of the DNA binding cavity and the fact that all contacts between DNA and the enzyme occur on one side of the DNA helix (5), it seems reasonable to assume that these insertion positions are located outside the actual enzyme-DNA contact region and thus are of minor importance for enzyme-DNA interactions.
Functional domains in eukaryotic topoisomerase II. It is not clear to what extent it will be possible to ascribe different functions of topoisomerase II to particular domains of the primary sequence. Deletion of individual conserved domains in human topoisomerase II␣ and S. cerevisiae topoisomerase II in all cases led to inactive, noncomplementing proteins, indicating that the conserved domains are critical for topoisomerase II function. However, the possibility that deletion of conserved domains, in some cases, may have obstructed correct folding of a functional enzyme cannot be ruled out.
It is interesting that domain 9 is consistent with a structural domain observed from the crystal structure to contain the active-site tyrosine in a CAP-like DNA binding region stretching from positions 702 to 790 in S. cerevisiae topoisomerase II. It has previously been suggested that Y-804, located in the equivalent domain of the human enzyme, constitutes the ac- Fig. 5 . The C-terminal truncation mutant proteins were examined for the ability to localize to the nucleus by indirect immunofluorescence (see Materials and Methods). wt-yTOPII with and without the tag refer to pYYP7 and pYTO300, respectively. Nucl. loc., nuclear localization. nd, not determined.
tive-site tyrosine (67) . Here we have demonstrated that a point mutation changing the tyrosine at position 804 to a serine residue abolishes complementation of the top2 null mutants and yields an inactive enzyme in vitro, indicating that Y-804 is the active-site tyrosine in human topoisomerase II␣. Domain 10, stretching from residues 808 to 895 in yeast topoisomerase II, covers a region in which a multitude of mutations giving rise to a temperature-sensitive or cold-sensitive phenotype have been mapped (29, 34, 55) . The fact that mutations scattered in this region exhibit the same phenotype suggests that the region executes a common function. Alignment of all eukaryotic topoisomerase II sequences has furthermore shown that the length of this particular region is highly conserved (29) . From the crystal structure, domain 10 constitutes a connecting region important for linking two major structural domains in the related gyrase subunit A fragment (11) . It is thus tempting to speculate that the sensitivity of domain 10 is due to involvement in the stabilization of DNA binding.
A number of studies have focused on identifying domains in topoisomerase II interacting specifically with anti-topoisomerase II agents (59) . This has led to the characterization of a multitude of mutations conferring resistance towards drugs such as etoposide and amsacrine. It is striking that the majority of these mutations are clustered in specific regions of topoisomerase II corresponding to domain 6 (13, 18, 62) in the N-terminal ATPase region and domains 9 (37) and 10 (29, 55) in the central region of the enzyme flanking the active site. That these specific domains interact with the topoisomerase II agents has been further supported by a genetic suppressor study in which peptides located in domains 9 and 10 represented the majority of genetic suppressor elements conferring drug resistance (25) .
Although some of the 13 domains defined in this study seem to constitute functional domains, the present analysis does not demonstrate whether any of these domains contain autonomous subfunctions or whether these depend on the presence of a multitude of domains and their accurate folding into larger structural entities. Further biochemical studies of our linker and deletion mutant proteins are necessary to elucidate the actual correspondence between enzymatic functions and structural domains in eukaryotic topoisomerase II.
Functions of the unconserved C-terminal domain in human topoisomerase II␣ and S. cerevisiae topoisomerase II. Only part of the divergent C-terminal region of human topoisomerase II␣ is dispensable for complementation in S. cerevisiae, as a truncation mutant deleted to position 1352 supported viability whereas this was lost with further truncation to position 1296. Loss of complementation does not correlate with loss of catalytic activity, as three constructs truncated to residues 1296, 1263, and 1233 exhibited decatenation activity yet failed to support viability. An explanation for this may be found in the altered localization pattern of these truncated proteins, as shown by immunostaining experiments with yeast cells. The enzyme truncated at residue 1352 was partially impaired with respect to nuclear localization, whereas the noncomplementing enzyme truncated at residue 1233 appeared only in the cytoplasm (Fig. 6 ). This observation is in correlation with the existence of a suggested NLS (KKQTTLAFKPIKKGKKR) between residues 1274 and 1290 (21) . Two additional mutants flanking this sequence, hC⌬1296 and hC⌬1263, were tested for cellular localization. Mutant hC⌬1296 was less abundant in the nucleus than was hC⌬1352, whereas hC⌬1263 gave a staining pattern similar to that obtained with hC⌬1233 (data not shown), in support of an NLS at the indicated position. Although the mutant truncated to residue 1296 was still detectable in the nucleus, it is likely that the inability of this enzyme to support viability reflects the slightly lower concentration of this enzyme than of hC⌬1352 in the nucleus. Identification of a region responsible for nuclear localization of human topoisomerase II␣ in the highly variable C-terminal part correlates with previous studies of topoisomerase II from S. pombe (50, 51) , D. melanogaster (19, 20) , and S. cerevisiae (17) .
In topoisomerase II from S. cerevisiae, the region between amino acids 1171 and 1334 has been shown to be important for nuclear transport of the enzyme (17) . In our study, we found that a mutant truncated to residue 1208 was still catalytically active although specific nuclear localization was lost in this mutant. A mutant truncated only to residue 1236 still located to the nucleus, indicating the importance of the residues between positions 1208 and 1236 for nuclear localization. The sequence between residues 1195 and 1211 in yeast topoisomerase II (RKLVDDEDYDPSKKNKK) has previously been identified as a potential NLS (21) . The observation that the construct ending at residue 1208, from which three residues of the proposed NLS have been removed, is located in the cytoplasm supports the suggested role of this sequence. It is possible, however, that since the bipartite nature of the NLS is not entirely destroyed, some specific localization to the nucleus still takes place. Our data are in agreement with earlier results obtained by Caron et al. with a mutant enzyme truncated to position 1208. In that case, the mutant enzyme was found to be marginally functional in vivo (17) .
Besides nuclear localization signals, the C-terminal region of eukaryotic topoisomerase II contains several potential phosphorylation sites (15, 65) , and this region has been assigned a function in the regulation of enzymatic activity via differential phosphorylation throughout the cell cycle (1, 14, 15, 31) . However, as the present study demonstrates, this type of regulation cannot be essential for the complementation ability of human topoisomerase II␣ and S. cerevisiae topoisomerase II during mitotic growth, since the phosphorylation sites (15, 65) can be deleted with no significant effect. Phosphorylation may, instead, fine-tune activity or relieve negative regulation during particular stages in the cell cycle, as suggested by Cardenas and Gasser (16) .
In summary, we have established a catalog of human topoisomerase II␣ and S. cerevisiae topoisomerase II linker insertion mutants in which the presence of pairs of unique compatible restriction sites conveniently enables the isolation, expression, and characterization of single conserved domains or arrays of conserved domains. The system can furthermore be applied for construction and analysis of chimeric proteins in which one or more domains have been exchanged between the yeast and human enzymes. Such studies will be valuable for further examination of the functional organization of eukaryotic topoisomerase II.
